Contemporary use of β-blockers: Clinical relevance of subclassification

Canadian Journal of Cardiology

Volumn 30, Issue 5 S, 2014, Pages

  Poirier, Luc ^a   Tobe, Sheldon W ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC SYSTEM; ANGINA PECTORIS; BRONCHUS REACTIVITY; CARDIOSELECTIVITY; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HEMODYNAMIC PARAMETERS; HUMAN; HYDROPHILICITY; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPOPHILICITY; META ANALYSIS (TOPIC); MORBIDITY; OUTCOME ASSESSMENT; REVIEW; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; CANADA; CARDIOVASCULAR DISEASES; DRUG UTILIZATION; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84899112661     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.12.001     Document Type: Review

References (71)

1. McKelvie R.S., Moe G.W., Ezekowitz J.A., et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 2013, 29:168-181.
2. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 61:e78-140.
3. Hackam D.G., Quinn R.R., Ravani P., et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013, 29:528-542.
4. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
5. Messerli F.H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998, 279:1903-1907.
6. Phillips S.M., Marton R.L., Tofler G.H. Barriers to diagnosing and managing heart failure in primary care. Med J Aust 2004, 181:78-81.
7. Everly M.J., Heaton P.C., Cluxton R.J. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004, 38:286-293.
8. Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003, 24:464-474.
9. Ubel P.A., Jepson C., Asch D.A. Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. JGen Intern Med 2003, 18:977-983.
10. Volpe M., Chin D., Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol 2010, 24:9-17.
11. Bradley H.A., Wiysonge C.S., Volmink J.A., Mayosi B.M., Opie L.H. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. JHypertens 2006, 24:2131-2141.
12. Poirier L., Lacourciere Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012, 28:334-340.
13. Arner P. The beta 3-adrenergic receptor-a cause and cure of obesity?. NEngl J Med 1995, 333:382-383.
14. Webb A.J., Fischer U., Rothwell P.M. Effects of β-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology 2011, 77:731-737.
15. Ahlquist R.P. Astudy of the adrenergic receptors. Am J Physiol 1948, 153:586-600.
16. Walker M.J. The major impacts of James Black's drug discoveries on medicine and pharmacology. Trends Pharmacol Sci 2011, 32:183-188.
17. Manrique C., Giles T.D., Ferdinand K.C., Sowers J.R. Realities of newer Beta-blockers for the management of hypertension. JClin Hypertens 2009, 11:369-375.
18. Frishman W.H., Saunders E. Beta-Adrenergic blockers. JClin Hypertens (Greenwich) 2011, 13:649-653.
19. Mason R.P., Giles T.D., Sowers J.R. Evolving mechanisms of action of beta blockers: focus on nebivolol. JCardiovasc Pharmacol 2009, 54:123-128.
20. De Caterina A.R., Leone A.M. The role of beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep 2011, 13:147-153.
21. Vanhoutte P.M., Gao Y. Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013, 13:265-273.
22. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000, 356:1955-1964. Blood Pressure Lowering Treatment Trialists' Collaboration.
23. Kuyper L.M., Khan N.A. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 2014, 30(5suppl):S47-S53.
24. Khan N., McAlister F.A. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737-1742.
25. Kamp O., Sieswerda G.T., Visser C.A. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003, 92:344-348.
26. De Caterina A.R., Leone A.M. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol 2010, 105:1433-1438.
27. Bangalore S., Steg G., Deedwania P., et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012, 308:1340-1349.
28. Gottlieb S.S., McCarter R.J. Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction. Am J Cardiol 2001, 87:823-826.
29. Beta-Blocker Heart Attack Trial Research Group. Arandomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982, 247:1707-1714.
30. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
31. Freemantle N., Cleland J., Young P., Mason J., Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318:1730-1737.
32. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
33. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. NEngl J Med 1996, 334:1349-1355.
34. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
35. Pedersen M.E., Cockcroft J.R. The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 2006, 8:279-286.
36. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
37. Ruwald M.H., Ruwald A.C., Jons C., et al. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). JAm Coll Cardiol 2013, 61:1518-1526.
38. White M., Desai R.V., Guichard J.L., et al. Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST. Can J Cardiol 2012, 28:354-359.
39. Flather M.D. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2004, 26:215-225.
40. Cruickshank J.M. Are we misunderstanding beta-blockers. Int J Cardiol 2007, 120:10-27.
41. Brixius K., Bundkirchen A., Bölck B., Mehlhorn U., Schwinger R.H. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001, 133:1330-1338.
42. Weber M.A. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 2005, 18:169S-176S.
43. Neutel J.M., Smith D.H., Ram C.V., et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993, 94:181-187.
44. Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
45. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
46. Wiysonge C.S., Bradley H.A., Volmink J., et al. Beta-blockers for hypertension (Review). Cochrane Database Syst Rev 2012, CD002003.
47. Park S., Rhee M.Y., Lee S.Y., et al. Aprospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients. JHypertens 2013, 31:813-819.
48. Hollenberg N.K. The role of beta-blockers as a cornerstone of cardiovascular therapy. Am J Hypertens 2005, 18:165S-168S.
49. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, CD003566.
50. Afonso R.A., Patarrao R.S., Macedo M.P., Carmo M.M. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens 2006, 19:419-425.
51. Pasini A.F., Garbin U., Stranieri C., et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008, 21:1251-1257.
52. Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. JCardiovasc Pharmacol 2009, 53:379-387.
53. Schiffrin E. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004, 17:1192-1200.
54. Mahmud A., Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008, 21:663-667.
55. Dhakam Z., Yasmin, McEniery C.M., et al. Acomparison of atenolol and nebivolol in isolated systolic hypertension. JHypertens 2008, 26:351-356.
56. Hashimoto J., Ito S. Aortic stiffness determines diastolic blood flow reversal in the descending thoracic aorta: potential implication for retrograde embolic stroke in hypertension. Hypertension 2013, 62:542-549.
57. Messerli F.H., Bangalore S., Yao S.S., Steinberg J.S. Cardioprotection with beta-blockers: myths, facts and Pascal's wager. JIntern Med 2009, 266:232-241.
58. Bangalore S., Parkar S., Grossman E., Messerli F.H. Ameta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007, 100:1254-1262.
59. Poirier L., Cléroux J., Nadeau A., Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. JHypertens 2001, 19:1429-1435.
60. Fonseca V., Bakris G.L., Bell D.S., et al. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med 2007, 24:759-763.
61. Bank A.J., Kelly A.S., Thelen A.M., Kaiser D.R., Gonzalez-Campoy J.M. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007, 20:777-783.
62. Vanbortel L., Bulpitt C., Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005, 18:1060-1066.
63. Grassi G., Trevano F.Q., Facchini A., et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003, 2:35-40.
64. Brixius K., Middeke M., Lichtenthal A., Jahn E., Schwinger R.H. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007, 34:327-331.
65. Prichard B.N. Pharmacologic aspects of intrinsic sympathomimetic activityin beta-blocking drugs. Am J Cardiol 1987, 59:13F-17F.
66. Cucherat M., Boissel J.P., Leizorovicz A. Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'Infarctus. Am J Cardiol 1997, 79:587-589.
67. Gray C.L., Ndefo U.A. Nebivolol: a new antihypertensive agent. Am J Health Syst Pharm 2008, 65:1125-1133.
68. Sica D.A., Black H.R. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy. Curr Hypertens Rep 2008, 10:330-335.
69. Deneer V.H., van Hemel N.M. Is antiarrhythmic treatment in the elderly different? A review of the specific changes. Drugs Aging 2011, 28:617-633.
70. Townend J.N., Littler W.A. Cardiac vagal activity: a target for intervention in heart disease. Lancet 1995, 345:937-938.
71. Ko D.T., Hebert P.R., Coffey C.S., Sedrakyan A., Curtis J.P., Krumholz H.M. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002, 288:351-357.